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illusTraTive case
a 70-year-old man with newly diagnosed 
hypertension comes to your office. you 
don’t want to prescribe a diuretic due to 
his history of gout. He has no history of 
coronary artery disease or heart failure. 
What is the best antihypertensive 
agent for him?
Background  
z		Guidelines	do	not		
reflect	new	evidence
Guidelines for the use of beta-blockers in 
the elderly do not reflect current evidence. 
JNC	recommendations
The 2003 JNC 7 Report recommended 
the same antihypertensive medications 
for adults of all ages.3 (JNC 7 is the 
most recent report from the Joint Na-
tional Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High 
Blood Pressure.)
JNC 7 recommends thiazide diuretics 
for first-line treatment of hypertension, 
and recommends other drugs—including 
beta-blockers, calcium-channel blockers, 
angiotensin-converting enzyme (ACE) 
inhibitors, and angiotensin receptor 
blockers (ARBs)—for first-line therapy if 
a thiazide is contraindicated, or in com-
bination with thiazides for higher initial 
blood pressure.
compelling indications. Beta-block-
ers are recommended in the JNC 7 Re-
port as first-line therapy in patients with 
“compelling indications” such as isch-
emic heart disease and heart failure.
clinical conTexT 
z	Seniors	taking	beta-	
blockers	to	their	detriment?
Many elderly patients are on beta-
blockers, perhaps to their detriment. 
Treatment choices for hypertension can 
have an enormous impact on outcomes 
among older patients:
Two thirds of US adults 60 years of 
age and older have hypertension, mostly 
isolated systolic hypertension.4,5 
Multiple studies, including the Sys-
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Beta-blockers should not  
be used to treat hypertension 
in patients older than age 60  
unless they have another  
compelling indication to 
use these agents, such as 
heart failure or ischemic 
heart disease.1,2 
Strength of recommendation 
a: Based on a well-done meta-analyses
Khan N, Mcalister Fa. re-examining the efficacy 
of beta-blockers for the treatment of hyperten-
sion: a meta-analysis. CMAJ 2006; 174:1737–
1742.1 
Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-
blockers for hypertension. Cochrane Database 
Syst Rev 2007; (1):CD002003.2
Practice changer 
Meta-analyses of 
beta-blocker trials 
show that they are 
inferior for first-
line hypertension 
treatment in the 
elderly who do not 
have heart failure 
or angina
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The  
criteria and findings leading  
to the selection of this study  
as a PURL can be accessed  
at www.jfponline.com/purls.
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In older patients, 
beta-blockers were 
associated with  
a higher risk of 
adverse outcomes
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tolic Hypertension in the Elderly Pro-
gram and the Systolic Hypertension in 
Europe, have shown that lowering blood 
pressure with pharmacologic interven-
tions in older patients can reduce the risk 
of cardiovascular events and possibly 
dementia.6
Beta-blockers have been a mainstay of 
hypertension treatment for many decades 
and we suspect continue to be widely 
used as first-line therapy in patients for 
whom the evidence now indicates they 
are inferior. 
sTudy summaries 
Two well-done reviews of beta-blocker 
trials show that they are inferior for first-
line hypertension treatment in the elderly 
who do not have heart failure or angina.
z	2007	Cochrane	review
The 2007 Cochrane review2 analyzed 
randomized trials that compared beta-
blockers for hypertension in adults 18 
years of age and older to each of the oth-
er major classes of antihypertensives. 
conclusion. This meta-analysis 
showed a “relatively weak effect of beta-
blockers to reduce stroke, and the absence 
of effect on coronary heart disease when 
compared with placebo or no treatment” 
and a “trend toward worse outcomes in 
comparison with calcium channel block-
ers, renin-angiotensin system inhibitors, 
and thiazide diuretics.”
This meta-analysis included all adults 
and did not make any conclusions based 
on age.
z	2006	CMAJ	meta-analysis
The Kahn and McAlister meta-analysis1 
pooled data from 21 randomized hyper-
tension trials (including 6 placebo-con-
trolled trials) that evaluated the efficacy 
of beta-blockers as first-line therapy for 
hypertension in preventing major cardio-
vascular outcomes (death, nonfatal MI, 
or nonfatal stroke). 
The results were analyzed by age 
group: trials enrolling patients with a 
mean age of 60 years or older at base-
line vs trials enrolling patients with a 
mean age of under 60 years.
conclusion. They concluded that 
in trials comparing other antihy-
pertensive medications with beta-
blockers, all agents showed similar 
efficacy in younger patients, while in older 
patients, beta-blockers were associated 
heart failure and angina  
are indications for beta-blockers
New evidence does not alter  
the 2003 JNC 7 recommendations 
to use beta-blockers as first-line 
therapy in patients with “compelling 
indications” such as ischemic  
heart disease and heart failure. 
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with a higher risk of both composite 
events and strokes (TABLE).
whaT’s new?  
z		The	age	distinction
These 2 meta-analyses1,2 help overturn a 
long-held belief about the value of beta-
blockers for the treatment of hyperten-
sion. Beta-blockers may not be a good 
first-line choice for any hypertensive 
patient—and the evidence clearly shows 
they are not a good first-line choice for 
patients over 60 years old. 
Two earlier systematic reviews did 
raise the concern about using beta-
blockers as first-line treatment for hy-
pertension (even when thiazides are not 
contraindicated). 
The first systematic review to raise 
this concern was a 1998 study of 10 hy-
pertension trials in more than 16,000 
patients, ages 60 and older. This review 
showed that diuretics were superior to 
beta-blockers in reducing cardiovas-
cular and all-cause mortality—which 
supports the JNC 7 recommendation 
to choose a thiazide diuretic as the first-
line drug of choice.7 
The second study, a meta-anal-
ysis published in 2005, also con-
cluded that beta-blockers should no 
longer be considered first-line therapy for 
hypertension, due to a 16% increase 
in the relative risk of stroke compared 
with other agents. This meta-analysis, 
however, did not report outcomes by 
patient age.8 
Beta-blockers	are	not	1st-line,	even		
if	thiazides	are	contraindicated
What is new about the Kahn and McAli-
ster evidence is that beta-blockers should 
not be the first-line drug of choice even 
when thiazide diuretics are contraindi-
cated. Their study included a larger num-
ber of trials (21 trials vs 13 in the 2005 
meta-analysis), which allowed the inves-
tigators to examine outcomes in patients 
younger than 60 and in those 60 years 
and older.
caveaTs  
z		Continue	beta-blockers		
for	the	right	reasons
Patients over 60 with ischemic heart dis-
ease or heart failure should still be pre-
scribed beta-blockers for heart failure 
and angina. Also, in older patients with 
hypertension who need multiple agents 
to control their blood pressure, a beta-
blocker could be added as a third or 
fourth agent in addition to a diuretic, 
ACE inhibitor, ARB, or calcium-channel 
blocker. Metoprolol is a good choice, as it 
is inexpensive and proven to reduce mor-
tality in patients with a history of MI or 
heart failure.
Atenolol	may	underperform
In a meta-analysis of 31 trials, 
Freemantle9 found that after MI, ace-
butolol, metoprolol, propranolol, and 
timolol significantly reduced mor-
tality, while there was no mortality 
reduction with atenolol. Similarly, in 
Changing our  
beliefs about  
beta-blockers  
may be our  
main challenge
Adverse	outcomes	more	likely	in	seniors	taking		
a	beta-blocker	vs	other	antihypertensives1	
  PaTienTs under age 60 PaTienTs age 60 and over
  adverse ouTcomes less  adverse ouTcomes more 
adverse ouTcome likely wiTh a BeTa-Blocker  likely wiTh a BeTa-Blocker 
composite outcomes rr=0.97 (95% CI, 0.88–1.07) rr=1.06 (95% CI, 1.01–1.1) 
(death, stroke, or MI) 
stroke rr=0.99 (95% CI, 0.67–1.44) rr =1.18 (95% CI, 1.07–1.3)
rr, relative risk of adverse outcomes, in randomized clinical trials of hypertensive  
patients treated with beta-blockers, compared with other antihypertensive drugs.
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heart failure, only bisoprolol, metoprolol, 
and carvedilol have evidence to support a 
reduction in mortality.10 
Although atenolol is one of the most 
commonly prescribed beta-blockers due 
to its low cost and once-daily dosing, it 
may be the least effective. In a system-
atic review of 9 hypertension studies, 
Carlberg11 showed that atenolol was no 
more effective than placebo at reducing 
MI, cardiovascular mortality, or all-cause 
mortality, and that patients on atenolol 
had significantly higher mortality than 
those taking other antihypertensives. 
Khan and McAlister do not differentiate 
between atenolol and other beta-blockers 
in their meta-analysis.1 
challenges To imPlemenTaTion  
z		Letting	go
The evidence supporting this change in 
practice has been accumulating over time. 
The change itself represents a significant 
reversal of long-standing belief in the val-
ue of beta-blockers as an antihypertensive 
agent. For each individual patient, the risk 
is not dramatic even though the cumula-
tive “harm” from using a beta-blocker 
compared to other options is potentially 
staggering because so many people over 
60 have hypertension. 
We suspect that the main challenge 
will be changing the beliefs of both phy-
sicians and patients. Once doctors are 
convinced that beta-blockers are not 
indicated for uncomplicated hyperten-
sion in patients over 60, changing medi-
cations in the millions of older patients 
who have been taking a beta-blocker 
for some time and have become com-
fortable with it will take tact and excel-
lent communication skills.
Providing patient information may 
help. Sources for patients are avail-
able free or at low cost at www.nhlbi.
nih.gov/health/public/heart/index.
htm#hbp. These materials explain that 
diuretics are inexpensive and are the 
preferred drugs for initial treatment of 
hypertension.   n
Purls methodology
This study was selected and evaluated using FPIN’s Priority updates 
from the research literature (Purl) Surveillance System method-
ology. The criteria and findings leading to the selection of this study 
as a Purl can be accessed at www.jfponline.com/purls.
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In patients over 60 who can’t tolerate a thiazide, the least  
expensive option is an aCE inhibitor. For example, in the 
Target and Walmart discount generic programs, benazepril, 
captopril, enalapril, and lisinopril are all available for  
$4 per month.
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